Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Marco L. Davila1, Isabelle Rivière2,3,1,4, Xiuyan Wang2, Shirley Bartido2, Jae H. Park1, Kevin J. Curran5, Stephen S. Chung1, Jolanta Stefanski2, Oriana Bórquez-Ojeda2, Malgorzata Olszewska2, Jinrong Qu2, Teresa Wasielewska2, Qing He2, Mitsú J. Fink2, Himaly Shinglot2, Maher Youssif2, Mark Satter2, Yongzeng Wang2, James Hosey2, Hilda Quintanilla1, Elizabeth Halton1, Yvette Bernal1, Diana Bouhassira3, Maria E. Arcila6, Mithat Gönen7, Gail J. Roboz8, P. Maslak1, Dan Douer1, Mark A. Schroeder9, Sergio Giralt3,1, Michel Sadelain3,1,4, Renier J. Brentjens3,1,4
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
2Cell Therapy and Cell Engineering Facility, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
3Center for Cell Engineering, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
4Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
5Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
6Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA
7Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
8Leukemia Service, NewYork-Presbyterian/Weill Cornell, New York, NY 10065, USA.
9Leukemia Service, NewYork-Presbyterian/Columbia, New York, NY 10032, USA.

Tóm tắt

CD19 CAR T cell therapy induces complete remissions in 88% of 16 adult patients with relapsed or refractory acute lymphoblastic leukemia.

Từ khóa


Tài liệu tham khảo

10.1126/scitranslmed.3005930

10.1056/NEJMoa1215134

10.1182/blood-2011-10-384388

10.1158/2159-8290.CD-12-0548

10.4161/onci.22524

10.1182/blood-2011-04-348540

10.1126/scitranslmed.3002842

10.1182/blood-2006-05-018192

10.1182/blood-2011-12-399287

10.1200/JCO.2012.46.2309

10.1016/j.coi.2013.09.017

10.1172/JCI200318921

10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O

10.1016/j.bbmt.2012.09.003

10.3324/haematol.2009.014274

10.1056/NEJMoa1103849

10.1038/mt.2009.83

10.1182/blood-2010-04-281931

10.4049/jimmunol.1301523

10.1182/blood-2013-02-485623

10.1056/NEJMoa063842

10.1371/journal.pone.0061338

10.1097/CJI.0b013e318194a6e8

10.1200/JCO.2003.04.036

10.1182/blood-2006-08-041152

M. Gönen Analyzing Receiver Operating Characteristic Curves with SAS (SAS Institute Cary NC 2007).

10.1002/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q

10.1182/blood.V60.3.677.677

10.1002/1097-0142(197307)32:1<69::AID-CNCR2820320109>3.0.CO;2-0